Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

被引：0
|
作者：
Matasar, Matthew J.
Haioun, Corinne
Sancho, Juan-Manuel
Viardot, Andreas
Izquierdo, Antonia Rodriguez
Martin, Eva Maria Donato
Garcia-Sancho, Alejandro Martin
Sandoval-Sus, Jose David
Tilly, Herve
Vandenberghe, Elizabeth
Hirata, Jamie
Choudhry, Priya
Chang, Yi Meng
Musick, Lisa
McMillan, Andrew
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Grp Hosp Henri Mondor, Lymphoid Malignancies Unit, Creteil, France
[3] ICO HU Germans Trias I Pujol, Barcelona, Spain
[4] Univ Hosp Ulm, Ulm, Germany
[5] Hosp Univ 12 Octubre, Serv Hemat, Madrid, Spain
[6] Hosp Univ Dr Peset Serv Hematol, Salamanca, Spain
[7] Hosp Clin Univ Salamanca, Serv Hematol, Salamanca, Spain
[8] Mem Healthcare Inst, Moffitt Canc Ctr, Pembroke Pines, FL USA
[9] Ctr Henri Becquerel, Dept Hematol, Rouen, France
[10] Ctr Henri Becquerel, U1245, Rouen, France
[11] Univ Rouen, Rouen, France
[12] St James Hosp Canc Clin Trials Off, Dublin, Ireland
[13] Genentech Inc, South San Francisco, CA USA
[14] F Hoffmann La Roche Ltd, Mississauga, ON, Canada
[15] Nottingham Univ Hosp NHS Trust, Ctr Clin Haematol, Nottingham, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7551
引用
收藏
页数：1
相关论文
共 50 条
  • [1] POLARGO: Randomized Phase III study of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Haioun, Corinne
    Matasar, Matthew J.
    Sancho, Juan-Manuel
    Viardot, Andreas
    Hernandez, Juana
    Perretti, Thomas
    McMillan, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Matasar, Matthew J.
    Haioun, Corinne
    Sancho, Juan-Manuel
    Viardot, Andreas
    Hirata, Jamie
    Perretti, Thomas
    Musick, Lisa
    McMillan, Andrew K.
    BLOOD, 2021, 138
  • [3] A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Hertzberg, Mark
    Ku, Matthew
    Catalani, Olivier
    Althaus, Betsy
    Simko, Stephen
    Gregory, Gareth P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Polatuzumab vedotin (Pola) plus rituximab (R) plus lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.
    Diefenbach, Catherine S. Magid
    Abrisqueta, Pau
    Gonzalez-Barca, Eva
    Panizo, Carlos
    Perez, Jose Maria Arguinano
    Miall, Fiona
    Bastos-Oreiro, Mariana
    Lopez-Guillermo, Armando
    Banerjee, Lalita
    McMillan, Andrew
    Hirata, Jamie
    Musick, Lisa
    Saha, Sourish
    Croft, Brandon
    Seymour, Erlene Kuizon
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Updated results of a phase Ib/II randomised study: polatuzumab vedotin (Pola) plus bendamustine (B) and rituximab (R) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Sehn, L. H.
    McMillan, A.
    Matasar, M. J.
    Flowers, C. R.
    Kamdar, M.
    Hertzberg, M.
    Assouline, S.
    Kim, T. M.
    Kim, W. S.
    Ozcan, M.
    Croft, B.
    Herrera, A. F.
    Hirata, J.
    Cheng, J.
    Ku, G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 93 - 94
  • [6] POLARGO: A Randomized Phase III Study Evaluating Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma Who Had Received One or More Previous Therapies
    McMillan, Andrew K.
    Matasar, Matthew J.
    Sancho, Juan-Manuel
    Viardot, Andreas
    Hernandez, Juana
    Perretti, Thomas
    Haioun, Corinne
    BLOOD, 2019, 134
  • [7] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    McMillan, A.
    Sehn, L.
    Herrera, A.
    Matasar, M.
    Kamdar, M.
    Assouline, S.
    Hertzberg, M.
    Kim, T. M.
    Kim, W. S.
    Ozcan, M.
    Hirata, J.
    Penuel, E.
    Cheng, J.
    Ku, G.
    Flowers, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 80 - 80
  • [8] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    Glass, B.
    Sehn, L. H.
    Herrera, A. F.
    Matasar, M.
    Kamdar, M.
    Assouline, S.
    Hertzberg, M.
    Kim, T. M.
    Kim, W. S.
    McMillan, A.
    Ozcan, M.
    Hirata, J.
    Penuel, E.
    Cheng, J.
    Ku, G.
    Flowers, C. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 3 - 3
  • [9] Glofitamab plus Polatuzumab Vedotin demonstrates durable responses and a manageable safety profile in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Dietrich, S.
    Hutchings, M.
    Avigdor, A.
    Sureda, A.
    Terol, M. J.
    Bosch, F.
    Corradini, P.
    Larsen, Stauffer T.
    Dominguez, Rueda A.
    Skarbnik, A.
    Jorgensen, J.
    Goldschmidt, N.
    Gurion, R.
    Zinzani, P. L.
    Pinto, A.
    Cordoba, R.
    Bottos, A.
    Huang, Z.
    Simko, S.
    Relf, J.
    de L'Etang, Filezac A.
    Sellam, G.
    Gritti, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 209 - 209
  • [10] Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study
    Sehn, Laurie H.
    Herrera, Alex F.
    Matasar, Matthew J.
    Kamdar, Manali
    Assouline, Sarit
    Hertzberg, Mark
    Kim, Tae Min
    Kim, Won-Seog
    McMillan, Andrew
    Ozcan, Muhit
    Hirata, Jamie M.
    Penuel, Elicia
    Cheng, Ji
    Ku, Grace
    Flowers, Christopher R.
    BLOOD, 2018, 132
12345